[go: up one dir, main page]

MX2021006768A - Metodos para tratar enfermedades oculares. - Google Patents

Metodos para tratar enfermedades oculares.

Info

Publication number
MX2021006768A
MX2021006768A MX2021006768A MX2021006768A MX2021006768A MX 2021006768 A MX2021006768 A MX 2021006768A MX 2021006768 A MX2021006768 A MX 2021006768A MX 2021006768 A MX2021006768 A MX 2021006768A MX 2021006768 A MX2021006768 A MX 2021006768A
Authority
MX
Mexico
Prior art keywords
methods
ocular diseases
treating ocular
weeks
administering
Prior art date
Application number
MX2021006768A
Other languages
English (en)
Inventor
Peter Sallstig
Werner Schmidt
Margarita Gekkieva
James Warburton
Andreas Weichselberger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54697654&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2021006768(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2021006768A publication Critical patent/MX2021006768A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
    • A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
    • A61B3/12—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporciona un método para reducir la carga del tratamiento para pacientes que padecen un trastorno neovascular intraocular, donde el método comprende administrar una cantidad terapéuticamente efectiva del antagonista del VEGF en una administración de la dosificación que incluye intervalos de tratamiento de 8 y/o 12 semanas.
MX2021006768A 2014-11-07 2017-05-04 Metodos para tratar enfermedades oculares. MX2021006768A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462076770P 2014-11-07 2014-11-07
US201462088061P 2014-12-05 2014-12-05

Publications (1)

Publication Number Publication Date
MX2021006768A true MX2021006768A (es) 2021-07-15

Family

ID=54697654

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2017005875A MX383399B (es) 2014-11-07 2015-11-06 Un antagonista anti-vegf para usarse en el tratamiento de enfermedades oculares.
MX2017005874A MX383808B (es) 2014-11-07 2015-11-06 Formulacion estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf.
MX2021006768A MX2021006768A (es) 2014-11-07 2017-05-04 Metodos para tratar enfermedades oculares.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2017005875A MX383399B (es) 2014-11-07 2015-11-06 Un antagonista anti-vegf para usarse en el tratamiento de enfermedades oculares.
MX2017005874A MX383808B (es) 2014-11-07 2015-11-06 Formulacion estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf.

Country Status (25)

Country Link
US (5) US10035850B2 (es)
EP (3) EP4684797A2 (es)
JP (6) JP6667519B2 (es)
KR (4) KR102588846B1 (es)
CN (4) CN114081951A (es)
AU (6) AU2015342815B2 (es)
BR (2) BR112017008093A2 (es)
CA (1) CA2966646A1 (es)
CL (2) CL2017001115A1 (es)
CO (1) CO2017004596A2 (es)
EA (1) EA201790989A1 (es)
EC (1) ECSP17034829A (es)
ES (1) ES3051145T3 (es)
GT (1) GT201700096A (es)
IL (5) IL251642B (es)
MX (3) MX383399B (es)
MY (2) MY193913A (es)
NZ (1) NZ730821A (es)
PE (1) PE20170780A1 (es)
PH (3) PH12021550147A1 (es)
RU (1) RU2722643C2 (es)
SG (3) SG11201702954XA (es)
TN (1) TN2017000128A1 (es)
TW (4) TWI705827B (es)
WO (2) WO2016073918A1 (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2004697A2 (en) 2006-04-07 2008-12-24 The Procter & Gamble Company Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
CN102076716A (zh) 2008-06-25 2011-05-25 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 抑制TNFα的稳定和可溶的抗体
ES2677003T3 (es) 2008-06-25 2018-07-27 Esbatech, An Alcon Biomedical Research Unit Llc Humanización de anticuerpos de conejo utilizando un marco universal de anticuerpos
WO2011005330A1 (en) 2009-07-06 2011-01-13 Akebia Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
MX385629B (es) 2011-01-13 2025-03-18 Regeneron Pharma Uso de un antagonista de factor de crecimiento endotelial vascular para tratar trastornos oculares angiogenicos.
CA2850830A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
WO2015138882A1 (en) 2014-03-14 2015-09-17 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
TWI705827B (zh) 2014-11-07 2020-10-01 瑞士商諾華公司 治療眼部疾病之方法
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
WO2016120753A1 (en) 2015-01-28 2016-08-04 Pfizer Inc. Stable aqueous anti- vascular endothelial growth factor (vegf) antibody formulation
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
MX387804B (es) 2015-09-23 2025-03-19 Aerpio Therapeutics Inc Metodos para tratar presion intraocular con activadores de tie-2
MX2018006767A (es) 2015-12-04 2019-03-14 Novartis Ag Composiciones y metodos para oncologia inmunologica.
EP3397276A4 (en) 2015-12-30 2019-12-18 Kodiak Sciences Inc. ANTIBODIES AND CONJUGATES THEREOF
KR20190031246A (ko) 2016-07-20 2019-03-25 에르피오 세러퓨틱스 인코포레이티드 VE-PTP (HPTP-β)를 표적으로 하는 인간화된 단클론성 항체
KR102124286B1 (ko) * 2016-09-07 2020-06-18 삭신 라이프사이언스 피브이티 엘티디 Vegf에 대한 합성 항체 및 이들의 용도
EP3518971A4 (en) * 2016-09-28 2020-05-13 Board Of Regents, The University Of Texas System ANTIBODIES AND THERAPEUTIC PROTEIN FORMULATIONS AND USES THEREOF
SG10201912529SA (en) 2016-11-18 2020-02-27 Astellas Pharma Inc Novel anti-human muc1 antibody fab fragment
BR112019018124A2 (pt) 2017-03-22 2020-04-07 Intellia Therapeutics Inc composições e métodos para imunooncologia
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
WO2018195912A1 (zh) * 2017-04-28 2018-11-01 苏州思坦维生物技术股份有限公司 一种眼用药物组合物及其用途
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
WO2019020777A1 (en) * 2017-07-26 2019-01-31 Formycon Ag LIQUID FORMULATION OF A VEGF ANTAGONIST
MX2020003043A (es) 2017-10-06 2020-10-05 Prothena Biosciences Ltd Métodos para detectar transtiretina.
EP3691447A4 (en) 2017-10-06 2021-08-11 Prothena Biosciences Limited ANTI-TRANSTHYRETINE ANTIBODY
MX2020005433A (es) 2017-11-29 2020-08-27 Prothena Biosciences Ltd Formulacion liofilizada de un anticuerpo monoclonal contra la transtirretina.
SG11202004268PA (en) 2017-11-30 2020-06-29 Regeneron Pharma Use of a vegf antagonist to treat angiogenic eye disorders
CN116059318A (zh) 2018-01-26 2023-05-05 加利福尼亚大学董事会 用于使用抗vegf剂治疗血管生成病症的方法和组合物
CN119733046A (zh) * 2018-02-06 2025-04-01 豪夫迈·罗氏有限公司 眼科疾病的治疗
KR20200140817A (ko) 2018-03-02 2020-12-16 코디악 사이언시스 인코포레이티드 Il-6 항체 그리고 이의 융합 작제물 및 접합체
KR20200131839A (ko) * 2018-03-16 2020-11-24 노파르티스 아게 안질환의 치료 방법
BR112020019065A2 (pt) * 2018-03-23 2020-12-29 AbbVie Deutschland GmbH & Co. KG Formulações de anticorpo anti-tau aquosas estáveis
CN112262158B (zh) * 2018-04-10 2024-08-09 奥美药业有限公司 新型血管生成素2，vegf双特异性拮抗剂
MX421310B (es) 2018-05-10 2025-03-14 Regeneron Pharma Formulaciones que contienen proteína de fusión del receptor de vegf a alta concentración
CA3100317A1 (en) 2018-05-17 2019-11-21 Astellas Pharma Inc. Complex having anti-human muc1 antibody fab fragment, peptide linker and/or ligand
CN120058958A (zh) * 2018-09-24 2025-05-30 视点制药公司 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
CN112839683B (zh) * 2018-10-10 2023-11-14 安斯泰来制药株式会社 含有标记部-抗人抗体Fab片段复合物的药物组合物
MX2021004774A (es) * 2018-10-29 2021-08-24 Hoffmann La Roche Formulacion de anticuerpos.
BR112021009001A8 (pt) 2018-11-07 2021-10-26 Applied Molecular Transport Inc Veículos derivados de cholix para administração oral de carga útil heteróloga
BR112021011290A2 (pt) * 2018-12-18 2021-11-03 Novartis Ag Formulação de solução de proteína contendo alta concentração de um anticorpo anti-vegf
KR102735988B1 (ko) 2019-02-18 2024-12-03 일라이 릴리 앤드 캄파니 치료 항체 제제
TWI862583B (zh) 2019-04-26 2024-11-21 美商愛德維仁生物科技公司 用於玻璃體內遞送之變異體aav蛋白殼
CA3138682A1 (en) 2019-04-29 2020-11-05 EyePoint Pharmaceuticals, Inc. Tie-2 activators targeting the schlemm's canal
WO2021034727A1 (en) 2019-08-16 2021-02-25 Applied Molecular Transport Inc. Compositions, formulations, and interleukin production and purification
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
CA3168512A1 (en) 2019-11-25 2021-06-03 Napoleone Ferrara Long-acting vegf inhibitors for intraocular neovascularization
CN111217834B (zh) * 2020-02-21 2021-10-26 维眸生物科技（上海）有限公司 Rock激酶抑制剂的硝基氧衍生物
CN115066262B (zh) * 2020-03-04 2025-07-15 上海复宏汉霖生物技术股份有限公司 一种包含贝伐珠单抗的药物配制剂
WO2021233408A1 (zh) * 2020-05-21 2021-11-25 迈威(上海)生物科技股份有限公司 抗α-溶血素的抗体及其稳定制剂
KR20220001106A (ko) * 2020-06-29 2022-01-05 (주)메디톡스 고농도 항-ｖｅｇｆ 항체 제제 및 이에 사용하기 위한 항-ｖｅｇｆ 항체
MX2023000547A (es) 2020-07-16 2023-02-13 Novartis Ag Anticuerpos anti-betacelulina, fragmentos de los mismos, y moleculas de union multiespecificas.
PE20240922A1 (es) * 2021-05-17 2024-04-30 Regeneron Pharma Regimenes de antagonistas del vegf en dosis alta extendidos para el tratamiento de trastornos oculares angiogenicos
CN113940997B (zh) * 2021-12-21 2022-04-08 迈威(上海)生物科技股份有限公司 一种双特异性抗体的稳定制剂
TW202412840A (zh) * 2022-09-16 2024-04-01 大陸商齊魯製藥有限公司 一種穩定的高濃度自緩衝藥物組合物
WO2025231345A1 (en) * 2024-05-03 2025-11-06 Therini Bio, Inc. Doses of antibodies which bind human fibrin yc or fibrinogen yc domain for ocular diseases

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
PT1802334E (pt) * 2004-10-21 2012-11-28 Genentech Inc Método para tratamento de doenças neovasculares intraoculares
WO2007011873A2 (en) * 2005-07-15 2007-01-25 Genentech, Inc. Method for treating intraocular neovascular diseases
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR101406811B1 (ko) 2006-06-16 2014-06-12 리제너론 파마슈티칼스 인코포레이티드 유리체내 투여에 적당한 ｖｅｇｆ 길항제 제형
PE20090329A1 (es) 2007-05-30 2009-03-27 Abbott Lab Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
AR069501A1 (es) 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
DK2307454T3 (en) * 2008-06-25 2017-04-24 Esbatech Alcon Biomed Res Unit Stable and soluble antibodies that inhibit VEGF
CN102076716A (zh) 2008-06-25 2011-05-25 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 抑制TNFα的稳定和可溶的抗体
ES2677003T3 (es) 2008-06-25 2018-07-27 Esbatech, An Alcon Biomedical Research Unit Llc Humanización de anticuerpos de conejo utilizando un marco universal de anticuerpos
WO2010006454A2 (en) 2008-06-30 2010-01-21 Esbatech, An Alcon Biomedical Research Unit Llc Functionalized polypeptides
KR20190067275A (ko) 2009-12-21 2019-06-14 제넨테크, 인크. 항체 제제
WO2012076670A2 (en) 2010-12-10 2012-06-14 Novartis Ag Antibody formulation
MX385629B (es) * 2011-01-13 2025-03-18 Regeneron Pharma Uso de un antagonista de factor de crecimiento endotelial vascular para tratar trastornos oculares angiogenicos.
KR20140045440A (ko) * 2011-06-30 2014-04-16 제넨테크, 인크. 항-c-met 항체 제제
RU2652886C2 (ru) * 2011-10-20 2018-05-03 ИЭсБиЭйТЕК-Э НОВАРТИС КОМПАНИ ЭлЭлСи Стабильные антитела, связывающиеся с несколькими антигенами
HK1208382A1 (en) 2012-05-03 2016-03-04 卡拉制药公司 Pharmaceutical nanoparticles showing improved mucosal transport
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
JOP20200175A1 (ar) 2012-07-03 2017-06-16 Novartis Ag حقنة
UA117466C2 (uk) * 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
CN110538322A (zh) 2013-03-13 2019-12-06 豪夫迈·罗氏有限公司 抗体配制剂
WO2015086830A1 (en) * 2013-12-13 2015-06-18 Delenex Therapeutics Ag Skin penetrating polypeptides
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
MX2016016836A (es) * 2014-06-17 2017-07-27 Clearside Biomedical Inc Metodos y dispositivos para tratar trastornos oculares posteriores.
TWI705827B (zh) 2014-11-07 2020-10-01 瑞士商諾華公司 治療眼部疾病之方法
US20160144025A1 (en) 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
KR20200131839A (ko) 2018-03-16 2020-11-24 노파르티스 아게 안질환의 치료 방법
BR112021011290A2 (pt) 2018-12-18 2021-11-03 Novartis Ag Formulação de solução de proteína contendo alta concentração de um anticorpo anti-vegf

Also Published As

Publication number Publication date
CN120938921A (zh) 2025-11-14
EA201790989A1 (ru) 2017-09-29
AU2020220210A1 (en) 2020-10-01
JP2020193212A (ja) 2020-12-03
JP2025004075A (ja) 2025-01-14
JP2020079242A (ja) 2020-05-28
MX383399B (es) 2025-03-13
CL2017001117A1 (es) 2018-01-26
AU2015342815B2 (en) 2018-12-13
AU2015342818A1 (en) 2017-05-11
EP3215123A1 (en) 2017-09-13
CN106999581A (zh) 2017-08-01
IL251696A0 (en) 2017-06-29
PH12017500843A1 (en) 2017-10-30
JP2017538674A (ja) 2017-12-28
AU2020244614B2 (en) 2023-06-01
US12371481B2 (en) 2025-07-29
PH12017500844A1 (en) 2017-10-30
JP2022141923A (ja) 2022-09-29
US20160340420A1 (en) 2016-11-24
PE20170780A1 (es) 2017-07-04
AU2020220210B2 (en) 2022-01-20
RU2017119647A (ru) 2018-12-07
TW201625221A (zh) 2016-07-16
EP3215122B1 (en) 2025-08-13
RU2017119647A3 (es) 2019-05-29
RU2020114917A (ru) 2020-05-22
MX2017005875A (es) 2017-06-26
IL265497B (en) 2021-06-30
GT201700096A (es) 2019-10-10
TWI705827B (zh) 2020-10-01
KR20230066649A (ko) 2023-05-16
PH12017500844B1 (en) 2021-05-05
WO2016073918A1 (en) 2016-05-12
BR112017008660A2 (pt) 2017-12-26
NZ730821A (en) 2019-11-29
MY193913A (en) 2022-11-01
KR102724014B1 (ko) 2024-10-31
EP3215122A1 (en) 2017-09-13
AU2018274882B2 (en) 2020-07-09
IL280087A (en) 2021-03-01
AU2015342818B2 (en) 2019-01-03
EP4684797A2 (en) 2026-01-28
CO2017004596A2 (es) 2017-08-31
JP6753848B2 (ja) 2020-09-09
MX383808B (es) 2025-03-14
JP7080263B2 (ja) 2022-06-03
TW201625306A (zh) 2016-07-16
EP3215122C0 (en) 2025-08-13
TWI761959B (zh) 2022-04-21
TWI806150B (zh) 2023-06-21
US20180298092A1 (en) 2018-10-18
ECSP17034829A (es) 2019-02-28
KR20170076781A (ko) 2017-07-04
TW202146049A (zh) 2021-12-16
IL283561A (en) 2021-07-29
CN107635580A (zh) 2018-01-26
ES3051145T3 (en) 2025-12-26
AU2018278870B2 (en) 2020-05-28
US10035850B2 (en) 2018-07-31
TWI738632B (zh) 2021-09-11
CA2966646A1 (en) 2016-05-12
US11098110B2 (en) 2021-08-24
PH12021550147A1 (en) 2023-01-23
CN114081951A (zh) 2022-02-25
AU2018274882A1 (en) 2018-12-20
IL251642B (en) 2021-02-28
SG10201913565RA (en) 2020-02-27
KR102588846B1 (ko) 2023-10-16
SG11201702954XA (en) 2017-05-30
CL2017001115A1 (es) 2018-01-26
KR20240161204A (ko) 2024-11-12
SG11201702909QA (en) 2017-05-30
US10689438B2 (en) 2020-06-23
IL280087B (en) 2022-02-01
AU2018278870A1 (en) 2019-01-03
KR20170082526A (ko) 2017-07-14
TN2017000128A1 (en) 2018-10-19
IL283561B (en) 2022-01-01
IL265497A (en) 2019-05-30
BR112017008093A2 (pt) 2018-03-13
IL251642A0 (en) 2017-06-29
JP2017534638A (ja) 2017-11-24
TW202103735A (zh) 2021-02-01
RU2020114917A3 (es) 2022-01-17
MY183807A (en) 2021-03-16
WO2016073915A1 (en) 2016-05-12
JP6667519B2 (ja) 2020-03-18
AU2020244614A1 (en) 2020-11-05
US20210340242A1 (en) 2021-11-04
RU2722643C2 (ru) 2020-06-02
US20200270336A1 (en) 2020-08-27
US12049495B2 (en) 2024-07-30
CA2966758A1 (en) 2016-05-12
US20160130337A1 (en) 2016-05-12
AU2015342815A1 (en) 2017-05-11
MX2017005874A (es) 2017-06-26

Similar Documents

Publication Publication Date Title
PH12017500843A1 (en) Methods for treating ocular diseases
MX2024004439A (es) Agentes terapeuticos para enfermedades neurodegenerativas
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MX2021009830A (es) Metodos para el tratamiento de trastornos del movimiento involuntario anormal.
SG10201808053XA (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
BR112017002637A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
BR112016000546A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
IL276383A (en) Treatment of ophthalmological diseases
MX2021000538A (es) Uso de sobetirome en el tratamiento de enfermedades de mielinizacion.
PH12015501531A1 (en) Crenolanib for treating flt3 mutated proliferative disorders
EA201791199A1 (ru) Способ лечения болезни альцгеймера
EP4324454A3 (en) Cross-linking agents and associated methods
PH12017500392A1 (en) Medical treatments based on anamorelin
PH12018502161A1 (en) Methods of treatment for cholestatic and fibrotic diseases
SG11202007433YA (en) Methods for managing behavioral treatment therapy and devices thereof
WO2019043649A3 (en) ANGIO -3 FOR THE TREATMENT OF RETINAL ANGIOGENIC DISEASES
SG11202100235YA (en) Prevention or treatment method for peripheral neuropathy or pain accompanying disease in which peripheral neuropathy or astrocyte disorder is recognized
BR112019004791A2 (pt) tratamento de esclerose múltipla com chs-131
SG11202010034WA (en) TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRß ANTIBODY
MY205171A (en) Methods of treatment of hypertriglyceridemia
MX2019004200A (es) Terapia de combinacion.
AR102494A1 (es) Métodos para tratar enfermedades oculares
PT4021505T (pt) Medicamento para o tratamento de doenças infecciosas
MA40574A (fr) Traitement de maladies fibrotiques
GB2603379B (en) Avocatin B for the treatment of diseases and conditions